中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1874-1879

Influence of metabolic associated fatty liver disease on the degree of carotid stenosis

DOI: 10.3969/j.issn.1001-5256.2023.08.016

  • Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, China

Research funding:

Yunnan Province "Ten Thousand Talents Plan" Famous Medical Talents Project (YNWR-MY-2019-074)

More Information
  • Corresponding author: ZHAO Gongfang, zhaogongfangedu@163.com (ORCID: 0000-0001-9178-1567)
  • Received Date: 2022-11-16
  • Accepted Date: 2023-01-13
  • Published Date: 2023-08-20
    Abstract
  •   Objective  To investigate the influence of metabolic associated fatty liver disease (MAFLD) on carotid stenosis.  Methods  This study was conducted among the patients who underwent abdominal ultrasound and cervical vascular ultrasound at the same time during hospitalization in Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, from January 1, 2014 to June 30, 2020, and baseline data and clinical diagnosis were collected. According to medical history, clinical tests, and imaging indicators, they were divided into MAFLD group with 469 patients and non-MAFLD group with 365 patients. Carotid artery were assessed as normal carotid artery, carotid stenosis < 50%, and carotid stenosis ≥50% according to the degree of stenosis. The independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed quantitative data between two groups; the chi-square test was used for comparison of qualitative data between two groups. The univariate and multivariate logistic regression analyses were used to investigate the influencing factors carotid stenosis.  Results  Compared with the non-MAFLD group, the MAFLD group had a significantly higher proportion of patients with carotid stenosis ≥50% (10.66% vs 5.21%, χ2=8.050, P=0.005). The univariate logistic regression analysis showed that there were significant differences between the two groups in the proportion of male patients, smoking, MAFLD, body mass index (BMI), total cholesterol, high-density lipoprotein (HDL), administration of lipid-lowering drugs, systolic pressure, hypertension or medication, type 2 diabetes, insulin resistance, and aspartate aminotransferase (AST). After adjustment for sex, smoking, HDL, BMI, history of hypertension or medication, type 2 diabetes, and AST, the multivariate logistic regression analysis showed that MAFLD was a risk factor for carotid stenosis (≥50%) (odds ratio=1.979, 95% confidence interval: 1.055-3.713, P=0.033).  Conclusion  MAFLD is an independent risk factor for carotid stenosis (≥50%).

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    ESLAM M, GEORGE J. Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice[J]. J Hepatol, 2020, 73(5): 1268-1269. DOI: 10.1016/j.jhep.2020.06.036.
    [2]
    LEI F, QIN JJ, SONG X, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China[J]. Front Endocrinol (Lausanne), 2022, 13: 1007171. DOI: 10.3389/fendo.2022.1007171.
    [3]
    OZTURK K, UYGUN A, GULER AK, et al. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men[J]. Atherosclerosis, 2015, 240(2): 380-386. DOI: 10.1016/j.atherosclerosis.2015.04.009.
    [4]
    BENJAMIN EJ, VIRANI SS, CALLAWAY CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association[J]. Circulation, 2018, 137(12): e67-e492. DOI: 10.1161/CIR.0000000000000558.
    [5]
    LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0.
    [6]
    KOZAKOVA M, PALOMBO C, ENG MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques[J]. Hepatology, 2012, 55(5): 1406-1415. DOI: 10.1002/hep.25555.
    [7]
    JOHRI AM, NAMBI V, NAQVI TZ, et al. Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: from the American Society of Echocardiography[J]. J Am Soc Echocardiogr, 2020, 33(8): 917-933. DOI: 10.1016/j.echo.2020.04.021.
    [8]
    YU C, WANG M, ZHENG S, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: a population-based prospective cohort study[J]. J Clin Transl Hepatol, 2022, 10(1): 6-16. DOI: 10.14218/JCTH.2021.00089.
    [9]
    SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22(8): 4156. DOI: 10.3390/ijms22084156.
    [10]
    DUAN Y, PAN X, LUO J, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298.
    [11]
    HUANG X, YAO Y, HOU X, et al. Macrophage SCAP contributes to metaflammation and lean NAFLD by activating STING-NF-κB signaling pathway[J]. Cell Mol Gastroenterol Hepatol, 2022, 14(1): 1-26. DOI: 10.1016/j.jcmgh.2022.03.006.
    [12]
    WU T, YE J, SHAO C, et al. Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease[J]. Front Endocrinol (Lausanne), 2021, 12: 691556. DOI: 10.3389/fendo.2021.691556.
    [13]
    ARROYAVE-OSPINA JC, WU Z, GENG Y, et al. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy[J]. Antioxidants (Basel), 2021, 10(2): 174. DOI: 10.3390/antiox10020174.
    [14]
    HERNANDEZ GV, SMITH VA, MELNYK M, et al. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): G582-G609. DOI: 10.1152/ajpgi.00344.2019.
    [15]
    YANG B, LUO W, WANG M, et al. Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response[J]. Biochim Biophys Acta Mol Basis Dis, 2022, 1868(10): 166480. DOI: 10.1016/j.bbadis.2022.166480.
    [16]
    HE Y, HWANG S, CAI Y, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes[J]. Hepatology, 2019, 70(4): 1150-1167. DOI: 10.1002/hep.30645.
    [17]
    YOU D, QIAO Q, ONO K, et al. miR-223-3p inhibits the progression of atherosclerosis via down-regulating the activation of MEK1/ERK1/2 in macrophages[J]. Aging (Albany NY), 2022, 14(4): 1865-1878. DOI: 10.18632/aging.203908.
    [18]
    ANSTEE QM, MANTOVANI A, TILG H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 425-439. DOI: 10.1038/s41575-018-0010-0.
    [19]
    GUO YC, ZHOU Y, GAO X, et al. Association between nonalcoholic fatty liver disease and carotid artery disease in a community-based Chinese population: a cross-sectional study[J]. Chin Med J (Engl), 2018, 131(19): 2269-2276. DOI: 10.4103/0366-6999.241797.
    [20]
    SINN DH, GWAK GY, CHO J, et al. Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease[J]. Atherosclerosis, 2014, 234(2): 270-275. DOI: 10.1016/j.atherosclerosis.2014.03.001.
    [21]
    CHEN Z, YANG YG. Guidelines for the diagnosis and treatment of carotid stenosis[J/CD]. Chin J Vasc Surg(Electronic Version), 2017, 9(3): 169-175. DOI: 10.3760.cma.j.issn.2096-1863.2017.02.003.

    陈忠, 杨耀国. 颈动脉狭窄诊治指南[J/CD]. 中国血管外科杂志(电子版), 2017, 9(3): 169-175. DOI: 10.3760.cma.j.issn.2096-1863.2017.02.003.
    [22]
    SINN DH, CHO SJ, GU S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis[J]. Gastroenterology, 2016, 151(3): 481-488. e1. DOI: 10.1053/j.gastro.2016.06.001.
    [23]
    HAACKE C, ALTHAUS A, SPOTTKE A, et al. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements[J]. Stroke, 2006, 37(1): 193-198. DOI: 10.1161/01.STR.0000196990.69412.fb.
    [24]
    PISTO P, SANTANIEMI M, BLOIGU R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study[J]. BMJ Open, 2014, 4(3): e004973. DOI: 10.1136/bmjopen-2014-004973.
    [25]
    Writing Group Members, LLOYD-JONES D, ADAMS RJ, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association[J]. Circulation, 2010, 121(7): e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.
    [26]
    LAL BK, DUX MC, SIKDAR S, et al. Asymptomatic carotid stenosis is associated with cognitive impairment[J]. J Vasc Surg, 2017, 66(4): 1083-1092. DOI: 10.1016/j.jvs.2017.04.038.
    [27]
    AMBROSETTI M, PEDRETTI RF. Does metabolic syndrome predict silent carotid stenosis in coronary patients?[J]. Intern Emerg Med, 2008, 3(1): 81-82. DOI: 10.1007/s11739-008-0103-9.
    [28]
    REN Z, SIMONS P, WESSELIUS A, et al. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study[J]. Hepatology, 2023, 77(1): 230-238. DOI: 10.1002/hep.32534.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (293) PDF downloads(34) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return